Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 220

1.

Metabolic syndrome among individuals with heroin use disorders on methadone therapy: Prevalence, characteristics, and related factors.

Vallecillo G, Robles MJ, Torrens M, Samos P, Roquer A, Martires PK, Sanvisens A, Muga R, Pedro-Botet J.

Subst Abus. 2017 Aug 3:1-6. doi: 10.1080/08897077.2017.1363122. [Epub ahead of print]

PMID:
28771091
2.

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.

Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L, Midgard H, Larney S, Degenhardt L, Alho H, Byrne J, Dillon JF, Feld JJ, Foster G, Goldberg D, Lloyd AR, Reimer J, Robaeys G, Torrens M, Wright N, Maremmani I, Norton BL, Litwin AH, Dore GJ; International Network on Hepatitis in Substance Users.

Int J Drug Policy. 2017 Sep;47:51-60. doi: 10.1016/j.drugpo.2017.05.019. Epub 2017 Jul 3.

PMID:
28683982
3.

Differences in the Rates of Drug Polyconsumption and Psychiatric Comorbidity among Patients with Cocaine Use Disorders According to the Mental Health Service.

Araos P, Vergara-Moragues E, González-Saiz F, Pedraz M, García-Marchena N, Romero-Sanchiz P, Ruiz JJ, Campos-Cloute R, Serrano A, Pavón FJ, Torrens M, Rodriguez De Fonseca F.

J Psychoactive Drugs. 2017 Jul 6:1-10. doi: 10.1080/02791072.2017.1342151. [Epub ahead of print]

PMID:
28682218
4.

Mephedrone Concentrations in Cases of Clinical Intoxication.

Papaseit E, Olesti E, de la Torre R, Torrens M, Farré M.

Curr Pharm Des. 2017 Jul 4. doi: 10.2174/1381612823666170704130213. [Epub ahead of print]

PMID:
28677506
5.

Patterns of use and toxicity of new para-halogenated substituted cathinones: 4-CMC (clephedrone), 4-CEC (4-chloroethcatinone) and 4-BMC (brephedrone).

Grifell M, Ventura M, Carbón X, Quintana P, Galindo L, Palma Á, Fornis I, Gil C, Farre M, Torrens M.

Hum Psychopharmacol. 2017 May;32(3). doi: 10.1002/hup.2621.

PMID:
28657185
6.

Non-Linear Formation of EtG and FAEEs after Controlled Administration of Low to Moderate Doses of Ethanol.

Pérez-Mañá C, Farré M, Pastor A, Fonseca F, Torrens M, Menoyo E, Pujadas M, Frias S, Langohr K, de la Torre R.

Alcohol Alcohol. 2017 Sep 1;52(5):587-594. doi: 10.1093/alcalc/agx033.

PMID:
28591763
7.

Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis.

Palma-Conesa ÁJ, Ventura M, Galindo L, Fonseca F, Grifell M, Quintana P, Fornís I, Gil C, Farré M, Torrens M.

J Psychoactive Drugs. 2017 Jun 1:1-9. doi: 10.1080/02791072.2017.1320732. [Epub ahead of print]

PMID:
28569652
8.

Substance-related psychopathology and aggressiveness in a nightlife holiday resort: Results from a pilot study in a psychiatric inpatient unit in Ibiza.

Martinotti G, Cinosi E, Santacroce R, Papanti D, Pasquini A, Mancini V, Corbo M, Fiori F, Sarchione F, Marchetti D, Verrocchio MC, Di Giannantonio M, Torrens M, Schifano F, Morlan Coarasa MJ, Merino Del Villar C.

Hum Psychopharmacol. 2017 May;32(3). doi: 10.1002/hup.2586. Epub 2017 May 30.

PMID:
28557062
9.

Dual diagnosis in Depression: treatment recommendations.

Tirado Muñoz J, Farré A, Mestre-Pintó J, Szerman N, Torrens M.

Adicciones. 2017 Jul 14;0(0):868. doi: 10.20882/adicciones.868. [Epub ahead of print] English, Spanish.

10.

Chronic Hepatitis C and people with a history of injecting drugs in Spain: population assessment, challenges for effective treatment.

Roncero C, Vega P, Martinez-Raga J, Torrens M.

Adicciones. 2017 Apr 11;29(2):71-73. doi: 10.20882/adicciones.908. English, Spanish.

11.

Concurrent Use of Cannabis and Alcohol: Neuropsychiatric Effect Consequences.

Romaguera A, Torrens M, Papaseit E, Arellano AL, Farré M.

CNS Neurol Disord Drug Targets. 2017;16(5):592-597. doi: 10.2174/1871527316666170419161839.

PMID:
28440194
12.

Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines.

Arellano AL, Papaseit E, Romaguera A, Torrens M, Farré M.

CNS Neurol Disord Drug Targets. 2017;16(5):554-566. doi: 10.2174/1871527316666170413104516.

PMID:
28412920
13.

Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment.

Roncero C, Littlewood R, Vega P, Martinez-Raga J, Torrens M.

Eur J Gastroenterol Hepatol. 2017 Jun;29(6):629-633. doi: 10.1097/MEG.0000000000000855.

PMID:
28230562
14.

Patients with alcohol use disorder: initial results from a prospective multicenter registry in the Spanish Network on Addiction Disorders. CohRTA Study.

Sanvisens A, Zuluaga P, Rivas I, Rubio G, Gual A, Torrens M, Short A, Álvarez FJ, Tor J, Farré M, Rodríguez de Fonseca F, Muga R.

Adicciones. 2017 Jul 14;0(0):931. doi: 10.20882/adicciones.931. [Epub ahead of print] English, Spanish.

15.

Illicit drug policy in Spain: the opinion of health and legal professionals.

Rossi P, Blay E, Costela V, Torrens M.

Adicciones. 2017 Jul 14;0(0):810. doi: 10.20882/adicciones.810. [Epub ahead of print] English, Spanish.

16.

Dual diagnosis: an European perspective.

Torrens M, Mestre-Pintó JI, Montanari L, Vicente J, Domingo-Salvany A.

Adicciones. 2017 Jan 1;29(1):3-5. doi: 10.20882/adicciones.933. English, Spanish.

17.

Plasma Chemokines in Patients with Alcohol Use Disorders: Association of CCL11 (Eotaxin-1) with Psychiatric Comorbidity.

García-Marchena N, Araos PF, Barrios V, Sánchez-Marín L, Chowen JA, Pedraz M, Castilla-Ortega E, Romero-Sanchiz P, Ponce G, Gavito AL, Decara J, Silva D, Torrens M, Argente J, Rubio G, Serrano A, de Fonseca FR, Pavón FJ.

Front Psychiatry. 2017 Jan 18;7:214. doi: 10.3389/fpsyt.2016.00214. eCollection 2016.

18.

Clinical Pharmacology of the Synthetic Cathinone Mephedrone.

Papaseit E, Moltó J, Muga R, Torrens M, de la Torre R, Farré M.

Curr Top Behav Neurosci. 2017;32:313-331. doi: 10.1007/7854_2016_61. Review.

PMID:
28012094
19.

Enhanced Activity and Acid pH Stability of Prussian Blue-type Oxygen Evolution Electrocatalysts Processed by Chemical Etching.

Han L, Tang P, Reyes-Carmona Á, Rodríguez-García B, Torréns M, Morante JR, Arbiol J, Galan-Mascaros JR.

J Am Chem Soc. 2016 Dec 14;138(49):16037-16045. Epub 2016 Dec 5.

PMID:
27960335
20.

The hidden web and the fentanyl problem: Detection of ocfentanil as an adulterant in heroin.

Quintana P, Ventura M, Grifell M, Palma A, Galindo L, Fornís I, Gil C, Carbón X, Caudevilla F, Farré M, Torrens M.

Int J Drug Policy. 2017 Feb;40:78-83. doi: 10.1016/j.drugpo.2016.10.006. Epub 2016 Nov 23.

PMID:
27889114

Supplemental Content

Loading ...
Support Center